Rousselot Biomedical will supply Gelomics with its gelatin methacryloyl, a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel 3D Tissue Culture System.
Rousselot, a collagen-based solutions provider, and Gelomics, a biotechnology company specializing in integrated 3D cell, organoid, and tissue culture technologies, announced a cobranding partnership on Nov. 16, 2022. Rousselot Biomedical will supply Gelomics with X-Pure GelMA (gelatin methacryloyl), a photo cross-linkable extracellular matrix, for use in Gelomics’ LunaGel 3D Tissue Culture System.
According to a company press release, gelatin methacryloyl is a biomaterial with tuneability and bioactivity that is used in various functions within engineering, 3D bioprinting, and 3D cell culture applications. Rousselot’s version is considered ultra pure (< 10 endotoxin units/gram) and is the first to be produced under current good manufacturing practice conditions. It will be available in ready-to-use kits in low and high stiffness formulations.
“The broad uptake of modern 3D cell culture techniques in biomedical R&D has been slowed down by a lack of easy-to-use and reproducible biomaterials that enable cells to grow and behave in a physiological manner,” said Christoph Meinert, CEO, Gelomics, in the press release. “We are pleased to partner with Rousselot Biomedical to overcome these limitations and provide the world’s first, ready-to-use 3D cell culture kits based on Rousselot Biomedical’s X-Pure GelMA.”
Source: Rousselot Biomedical